# PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

> **NCT00004002** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health**

## Conditions studied

- Lymphoma
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00004002
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2001-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004002, "PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00004002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*